Original Article httpsdoiorg103947ic2016484274 Infect Chemother 2016484274284 ISSN 20932340 Print ISSN 20926448 Online Infection Chemotherapy Clinical Therapeutic Implications Aeromonas Bacteremia 14 Years NationWide Experiences Korea Ji Young Rhee1 Dong Sik Jung2 Kyong Ran Peck3 1Division Infectious Diseases Department Medicine Dankook University Hospital Cheonan 2Division Infectious Diseases De partment Medicine DongA University Hospital Busan 3Division Infectious Diseases Samsung Medical Center Sungkyunkwan University School Medicine Seoul Korea Background To elucidate clinical presentation antimicrobial susceptibility prognostic factors monomicrobial Aero monas bacteremia order determine effective optimal therapy Materials Methods We reviewed medical records Aeromonas bacteremia patients period January 2000 December 2013 retrospective multicenter study Results A total 336 patient records reviewed 242 having communityacquired bacteremia The major clinical fections hepatobiliary tract 506 peritonitis 185 followed primary bacteremia 179 The infections usually occurred patients malignancy 423 hepatic cirrhosis 393 diabetes mellitus 256 High antimicro bialresistance rates 155 ceftriaxone 155 piperacillintazobactam noted However resistance carbape nem amikacin 98 30 respectively Aeromonas hydrophila 589 common pathogen followed Aeromonas caviae 304 The severity A caviae bacteremia cases A hydrophila Aer omonas veronii bacteremia P 005 A hydrophila showed higher antimicrobial resistance Aeromonas species P 005 Patients hospitalacquired bacteremia likely severely abnormal laboratory findings rel atively high antimicrobialresistance rates Mortality associated metastatic cancer shock delayed use appropriate antimicrobial agents increased prothrombin time increased creatinine level P 005 Conclusions Aeromonas species considered causative agents bacteremia patients intraabdominal infections malignancies Although ceftriaxoneresistant Aeromonas bacteremia statistically related mortality study associated severe clinical manifestations laboratory abnormalities Appropriate antibiotics including car bapenem administered early especially Aeromonas bacteremia patients shock impaired renal function Key Words Aeromonas Antimicrobial resistance Bacteremia Risk factors Received September 1 2016 Accepted November 21 2016 Publised online December 12 2016 Corresponding Author Kyong Ran Peck MD PhD Division Infectious Diseases Department Medicine Samsung Medical Center Sungkyunkwan University School Medicine 81 Irwonro Gangnamgu Seoul 06351 Korea Tel 82234100329 Fax 82234100041 Email krpeckskkuackr This Open Access article distributed terms Creative Commons Attribution NonCommercial License httpcreativecommonsorglicensesbync30 permits unrestricted noncommercial use distribution repro duction medium provided original work properly cited Copyrights 2016 The Korean Society Infectious Diseases Korean Society Chemotherapy wwwicjournalorg 03원저_16613_이지영백경란indd 1 20161228 오후 33511 wwwicjournalorg httpsdoiorg103947ic2016484274 Infect Chemother 2016484274284 275 Introduction Material Methods Aeromonas species belonging genus Aeromonas oxidaseproducing Gramnegative rods grow Mac Conkey agar ferment carbohydrates 1 These aquatic mi croorganisms associated variety human diseases 1 Aeromonas species proliferative omnipres ent fresh water soils 2 occasionally isolat ed feces healthy people 3 Among 14 known spe cies identified genus Aeromonas considered pathogenic 4 More 85 Aero monasimplicated clinical diseases caused Aero monas hydrophila Aeromonas caviae Aeromonas veronii biovar sobria 2 These infections acquired commu nity hospital settings immunocompetent immunocompromised patients susceptible Aeromonas species cause invasive fatal infections immunocom promised hosts recognized threat human beings 4 The Aeromonas infectionrelated disease spectrum hu mans expanded includes acute gastroenteritis bac teremia pancreatitis hepatobiliarytract infections softtissue infections indwellingdevicerelated infections brain abscess es meningitis endocarditis pleuropulmonary infections peri tonitis hemolyticuremic syndrome 18 The com mon underlying conditions known associated Aeromonas bacteremia malignancy hepatobiliary dis eases 5 Aeromonas spp tend produce ßlact amases penicillinase cephalosporinase carbap e n e ma s e w h c h l l c h ro m o s o m e e n c o d e d 6 Nevertheless date antibiotic resistance major problem strains isolated environment In contrast clinical studies Aeromonas infections relatively rare relevant antibiotic susceptibility profile accordingly mains vague Previous studies attempted identify risk factors studies considered risk fac tors resistance limited number antimicrobials 2 7 8 Aeromonas bacteremia patients cirrhosis malig nancy associated higher mortality rate bacteremia caused organisms 8 The pres ent study largest retrospective clinical investigation alyze data monomicrobial Aeromonas bacteremia The objectives study elucidate clinical characteristics Aeromonas bacteremia scrutinize antimicrobial susceptibility Aeromonas optimal therapy We aimed identify risk factors mortality patients Aeromonas bacteremia 1 Patients We retrospectively reviewed medical records patients diagnosed Aeromonas bacteremia January 2000 December 2013 multiple centers Sam sung Medical Center Seoul Dankook University Hospital Cheonan DongA University Hospital Busan Jeju Uni versity Hospital Jeju Patient records information anonymized deidentified prior analysis Institutional review board approval obtained retrospective evalua tion patients DKUH 201501014 Aeromonas bacteremia defined presence Aeromonaspositive blood culture concomitant signs symptoms infection When patients blood culture yielded type pathogen monomicrobial bactere mia diagnosed type pathogen identified diagnosis polymicrobial bacteremia We included patients monomicrobial bacte remia analysis Hospitalacquired infections fined bacteremic episodes detected 72 h ad mission patients showed clinical evidence bacteremia admission Information age sex underlying disease blood laborato ry data culture results probable portals entry type anti microbial agents treatment type medical procedure treatment clinical outcome collected patients Illness severity comorbidity patients presentation bacteremia hospital graded Pitt bacteremia score 5 9 Charlsons weighted comorbidity index 5 respectively Patients Aeromonas bacteremia surveyed concomitant infection foci lacking foci classified having primary bac teremia 2 Antimicrobial susceptibility test Aeromonas isolates obtained processing blood culture samples BACTEC Model 9240 BD Diagnostic In strument Systems Sparks MD USA BacTALERT 3D bio Merieux Inc Haselwood MO USA Aeromonas identi fied means standard identification card Antibiotic susceptibility testing isolates carried au tomated hospital Qualitycontrol protocols minimum inhibitory concentration breakpoints MICs compliance standards established Clinical Laboratory Standards Institute 10 03원저_16613_이지영백경란indd 2 20161228 오후 33513 276 Rhee JY et al Clinical implications Aeromonas bacteremia wwwicjournalorg 3 Statistical analysis Statistical analyses carried SPSS 130 SPSS Inc Chicago IL USA Continuous variables expressed mean standard deviation SD median range ac cording homogeneity The categorical variables compared ChiSquare test Fisher s exact test necessary The quantitative variables compared StudentFisher t test analysis variance The risk factors infectionrelated mortality evaluated uni variate multivariate logistic regression analyses Factors Pvalue 02 univariate analysis excepting considered strongly associated variables entered multiple logistic regression analysis A value P 005 considered statistically significant Results 1 Patient characteristics Eighthundredandtwentyfour cases Aeromonas bacte remia enrolled 488 cases polymicrobial Aeromonas bacteremia observed The remaining 336 monomicrobial Aeromonas bacteremia cases included study Table 1 The major causes bacteremia hepatobiliary tract infections 506 followed peritonitis 185 primary bacteremia 179 Communityac quired bacteremia shown 242 cases 720 The infec tions usually occurred patients solidorgan malignan cy 423 hepatic cirrhosis 393 diabetes mellitus 256 leukemia 71 Concomitant anticancer chemo therapy administered 74 patients 220 The leading clinical manifestations fever 387 septic shock 256 altered consciousness 179 Initial age inappropriate antimicrobial agent noticed 140 cases Onehundredandsixtysix cases showed antimicrobi alagent combination therapy The median duration treat ment 10 days In 272 cases antimicrobialagent initiation 6 h symptom manifestations observed Fifty pa tients died Aeromonas bacteremia 2 Seasonal distribution Aeromonas bacteremia A trend frequent occurrence warm er seasons May October n 232 690 observed Most communityacquired infections 176 242 727 occurred seasons Fig 1 3 Differences clinical characteristics antimicrobial susceptibility species A hydrophila frequently involved primary bacte remia frequent skin softtissue infections peritonitis P 005 infections species Table 2 A caviae prevalent skin softtissue infections P 0009 prevalent primary bactere mia P 0017 infections species Sponta neous bacterial peritonitis SBP common A hydrophila infections 5062 SBP cases Pneumonia common Aeromonas salmonicida infection P 0001 Hospitalacquired infections common pa tients A caviae A salmonicida infections P 0001 Table 1 Characteristics enrolled patients Characteristics Age year median Sex ratio malefemale Value 57 236 236100 Communityacquired Hospitalacquired 24294 Underlying diseases Solid organ malignancy Hepatic cirrhosis Diabetes mellitus Leukemia Concomitant chemotherapy Clinical manifestations Fever 38C Hypothermia Shock Altered consciousness Abdominal pain Dyspnea Site infection Hepatobiliary infections Peritonitis Primary bacteremia Pneumonia Skin softtissue infection Catheter related infection Usage Antimicrobial agent Initial Appropriate Inappropriate Combination therapy Duration treatment days median Number patients antimicrobi al agents initiated 6 h symptom manifestation 142 423 132 393 86 256 24 71 74 220 130 387 34 101 86 256 60 179 52 155 48 143 170 506 62 185 60 179 20 59 14 42 10 30 196140 166 494 10 272 810 03원저_16613_이지영백경란indd 3 20161228 오후 33513 wwwicjournalorg httpsdoiorg103947ic2016484274 Infect Chemother 2016484274284 277 y c n e u q e r F 50 45 40 35 30 25 20 15 10 5 0 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Month Figure 1 Monthly distribution Aeromonas bacteremia Underlying diseases differed according species A veronii A sorbia infections frequent liver cirrhosis A caviae A sorbia infections frequent pa tients solidorgan cancers A salmonicida infections common leukemia Moreover A caviae fections occurred frequently concurrent chemo therapy P 0004 A hydrophila tended present cases shock P 0001 Liver function test results worse cases A hydrophila infection cases infec tions involving species P 0001 A hydrophila accounted 589 cases 102 cases A caviae 304 20 cases A sobria 60 10 cas es A veronii 30 cases A salmonicida 17 infections Table 2 All 336 isolates included analysis antimicrobi al susceptibility More 90 cases susceptible ceftazidime ciprofloxacin imipenem gentamicin amikacin Among distinct Aeromonas complexes identified A hydrophila resistant antimi crobial agents The exceptions Aeromonas isolates Jeju University Hospital 20 100 cases sus ceptible piperacillin piperacillintazobactam ceftriaxone ceftazidime imipenem ciprofloxacin tobramycin gentami cin amikacin 4 Comparison communityacquired hospital acquired Aeromonas bacteremia No clustered cases hospitalacquired Aeromonas bactere mia noted Individual cases developed 442 days median 10 days admission Communityacquired Aer omonas bacteremia differed hospitalacquired bactere mia aspects Table 3 A total 242 patients diagnosed communi tyacquired Aeromonas bacteremia Univariate analysis vealed statistically significant differences age ICU admis sion hospital stay site infection underlying diseases liver cirrhosis leukemia concurrent chemotherapy presence central line catheter blood laboratory results hemoglobin prothrombin time PT activated partial thromboplastin time aPTT aspartate transaminase AST bilirubin glucose presence cardiopulmonary resuscitation species differenc es proportion initial discordant antimicrobial agent use initiation appropriate antimicrobial agent 6 h timicrobial resistance community hospitalac quired Aeromonas bacteremia Hepatobiliary infections P 0003 spontaneous bacterial peritonitis P 0038 common communityacquired bacteremia primary bacteremia P 0003 pneumonia P 0002 cathe terrelated infection P 0000 common hospi talacquired bacteremia Liver cirrhosis common derlying condition communityacquired bacteremia P 0023 leukemia P 0001 concurrent chemo therapy P 0002 common underlying conditions hospitalacquired bacteremia The laboratory findings abnormal cases hospitalacquired bacteremia P 0009 0045 5 Antimicrobial therapy Empirical therapy Twelve patients died septic shock multiorgan failure appropriate antimicrobial agent treatment started A total 140 cases started inappropriate antibiotics half patients 166 administered combination therapy 56 placed aminoglycoside combination therapy The common ini tially administered antimicrobial agents ceftriaxone metronidazole 100 cases Ceftriaxone single common agent empirical therapy Aeromonas bacte remia 611 Definitive therapy The therapeutic efficacy definitive therapy evaluated 310 patients There statisti cally significant differences mortality monothera py combination therapy P 0050 Time start antimicrobial agents There statis tically significant difference mortality 6 h prior initiation appropriate antimicrobial agents P 0049 6 Ceftriaxone resistance Among 336 cases Aeromonas monomicrobial bacteremia 284 845 caused ceftriaxonesusceptible CS Aeromonas bacteremia 52 155 ceftriaxoneresis 03원저_16613_이지영백경란indd 4 20161228 오후 33514 278 Rhee JY et al Clinical implications Aeromonas bacteremia wwwicjournalorg s n o m o r e A d c n o m l s 6 n s n o m o r e A s n o m o r e A s n o m o r e A n o r e v 0 1 n r b o s 0 2 n e v c 2 0 1 n s n o m o r e A l h p o r d y h 8 9 1 n m e r e t c b o nicid alm s s n o m ero A d n nii ero s v n o m ero bria A o s s n o m ero e A s c n o m ero hila A p dro y s h n o m ero A n y t l b t p e c s u s l b o r c m t n d n s g n d n fi t y r o r o b l n o t t n e s e r p l c n l C 2 e l b T e u l v P 5 0 6 0 2 3 0 0 1 0 0 0 1 0 0 0 4 0 0 0 2 8 1 0 1 0 0 0 1 0 0 0 1 0 0 0 4 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 5 6 0 0 1 0 0 0 1 0 0 0 7 6 6 4 0 4 1 0 1 0 0 0 6 1 1 0 3 0 0 0 7 1 0 0 3 3 3 2 3 3 3 2 0 0 0 0 1 0 0 0 7 6 6 4 3 9 6 2 4 7 6 4 0 0 2 7 6 9 3 0 0 2 2 0 0 2 2 0 0 6 6 0 0 2 2 0 0 0 0 3 3 5 2 8 0 6 2 0 0 5 0 2 2 1 9 0 0 0 0 0 0 0 2 2 3 3 3 2 0 0 0 0 3 3 3 2 7 6 6 4 7 6 6 4 7 6 6 4 3 3 3 2 0 0 0 0 0 1 6 0 0 0 0 4 4 0 0 8 8 0 0 4 4 0 0 2 2 0 0 2 2 0 0 0 0 0 0 0 0 4 4 0 0 3 3 0 0 0 0 1 2 0 0 2 1 4 2 4 8 1 1 2 1 0 0 5 0 1 8 0 6 2 6 0 0 1 2 0 0 4 8 0 0 0 0 0 0 4 8 0 0 7 4 1 0 0 9 8 1 0 0 0 0 5 0 1 0 0 0 0 0 0 0 0 0 0 0 0 4 8 8 7 8 6 1 2 2 2 9 3 4 0 0 4 9 2 0 3 4 1 3 2 3 0 1 5 2 5 6 9 1 2 5 7 2 8 2 6 9 1 0 2 7 5 1 6 1 0 0 7 3 1 4 1 0 9 4 0 5 8 8 5 0 6 2 2 2 4 4 2 7 1 4 3 5 5 4 0 9 3 5 2 0 5 2 5 1 0 3 1 6 2 1 1 6 2 1 2 1 2 2 4 4 9 3 8 7 3 4 3 8 6 0 2 4 2 7 1 4 3 3 8 2 6 5 3 1 3 2 6 1 7 4 1 3 3 3 6 6 0 4 5 7 0 1 5 2 4 5 4 6 1 0 8 0 0 4 6 0 6 8 8 3 5 0 2 2 8 2 1 1 2 0 4 5 4 9 1 5 6 5 2 7 6 2 1 8 9 1 9 3 4 0 9 5 3 n e m x e d n y t d b r o m o c d e t h g e w n o s l r h C n e m e r o c s m e r e t c b t t P e l m e F e l M x e S n e m e g A s e l b r V m e r e t c b d e r u q c l t p s o H n e m y d y t s l t p s o H n o t c e f n f o e c r u o S y t l t r o M s n o t c e f n y r l b o t p e H m e r e t c b y r m r P n o m u e n P s t n o t r e P s n o t c e f n e u s s t t f o s d n n k S y c n n g l m n g r o d l o S k c t t r l u c s v o r b e r e C y p r e h t o m e h c t n e r r u c n o C n o t z r e t e h t c s u o n e v l r t n e C n o t z r e t e h t c y r n r U e t t s d e t s s s r o t l t n e V k c o h S s u t l l e m s e t e b D s s o h r r c c t p e H s e s e s d g n y l r e d n U s t n e g l b o r c m t n f o n o t n b m o c e s U 0 0 8 1 0 4 8 0 4 9 9 6 2 1 3 2 1 1 n e m y d e s u t n e g l b o r c m t n f o n o t r u D 4 6 3 2 7 e s u t n e g l b o r c m t n e t r p o r p p n I 03원저_16613_이지영백경란indd 5 20161228 오후 33514 wwwicjournalorg httpsdoiorg103947ic2016484274 Infect Chemother 2016484274284 279 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 4 1 0 0 3 0 0 0 1 0 0 0 2 0 0 0 1 0 0 0 4 3 3 0 1 2 0 0 1 0 0 0 4 2 0 0 7 2 1 0 e u l v P s n o m o r e A d c n o m l s 6 n s n o m o r e A s n o m o r e A s n o m o r e A n o r e v 0 1 n r b o s 0 2 n e v c 2 0 1 n s n o m o r e A l h p o r d y h 8 9 1 n 2 0 7 1 3 3 6 2 2 0 0 2 9 2 3 3 9 9 4 7 6 0 4 1 0 0 2 7 0 6 0 8 1 1 3 0 9 2 3 0 1 2 0 0 1 0 4 2 7 0 0 5 6 1 0 0 3 5 1 0 0 6 9 5 0 0 4 4 3 1 7 7 3 7 1 4 1 7 4 2 1 1 3 8 4 0 1 9 5 0 7 2 3 1 0 0 9 5 1 0 5 6 5 0 9 2 4 8 7 2 0 6 1 6 7 5 4 3 9 0 n s e c e p s n h t w y t l b t p e c s u S 6 6 6 1 3 5 6 3 1 8 1 2 6 1 3 6 7 1 2 7 2 6 8 2 1 3 4 8 1 0 2 6 8 9 1 7 9 7 4 0 2 1 5 4 2 1 5 3 8 1 1 6 7 4 6 1 5 9 0 8 3 0 3 9 0 2 3 3 0 4 1 2 6 6 1 0 2 9 2 5 5 7 2 1 n n e m L U I P L A e s t h p s o h p e n l k l A n e m L U T S A e s n m s n r t e t t r p s A 3 m m r e b m u n t n u o c l l e c d o o b e t h W l s g n d n fi y r o t r o b L 3 m m 3 0 1 t e l e t l P L d g m e s o c u G l d e u n t n o C 2 e l b T s e l b r V n e m L U T L A e s n m s n r t e n n l A c e s T T P e m t n t s l p o b m o r h t l t r p d e t v t c n e m R N I T P e m t n b m o r h t o r P L d g m e n n t e r C s e t l o s l l n h t w y t l b t p e c s u s t n e g l b o r c m t n A L d g m n b u r l B 1 0 0 0 3 3 3 2 0 0 0 0 3 3 3 2 3 3 3 2 3 3 3 2 3 3 3 2 0 0 1 6 0 0 1 6 0 0 1 6 0 0 1 6 0 0 1 6 0 0 0 0 0 0 1 0 1 0 0 1 0 1 0 8 8 0 0 1 0 1 0 0 1 0 1 0 0 1 0 1 0 8 8 0 8 8 0 0 1 0 1 0 8 8 0 2 4 0 5 0 1 0 0 1 0 2 0 0 1 0 2 0 0 1 0 2 0 0 1 0 2 0 0 1 0 2 0 0 1 0 2 0 7 4 1 0 0 1 0 2 0 0 1 0 2 7 5 1 6 1 4 1 3 2 3 4 0 8 2 8 2 0 9 2 9 4 2 8 4 8 1 6 9 8 9 2 8 8 0 9 0 4 8 3 5 2 0 5 9 8 2 2 9 m t c b u S n l l l c p m A 3 8 8 2 n l l c p m A 8 7 7 4 5 1 8 0 8 0 6 1 9 5 8 0 7 1 9 1 9 2 8 1 9 9 8 6 7 1 5 4 8 4 8 2 m t c b o z T n l l c r e p P 5 4 8 4 8 2 e n o x r t f e C 9 2 9 2 1 3 e m d z t f e C 9 9 8 2 0 3 n c x o fl o r p C 8 9 7 8 6 2 n l l c r e p P 0 0 1 2 0 1 3 3 8 5 6 1 2 0 9 3 0 3 m e n e p m I 0 8 9 0 0 1 0 8 9 0 0 1 8 0 8 0 6 1 9 9 8 8 7 1 0 0 1 2 0 1 9 4 9 8 8 1 7 5 8 8 8 2 n c y m r b o T 9 2 9 2 1 3 n c m t n e G 0 7 9 6 2 3 n c k m A 0 0 1 0 2 1 5 9 7 9 3 4 8 7 6 1 8 7 8 4 9 2 e l o z x o h t e m f l u S m r p o h t e m r T 03원저_16613_이지영백경란indd 6 20161228 오후 33515 280 Rhee JY et al Clinical implications Aeromonas bacteremia wwwicjournalorg tant CR Aeromonas bacteremia Table 3 The CS CR Aeromonas bacteremia groups similar demographic characteristics There higher rate mortality CR Aeromonas bacteremia group difference sta tistically significant P 0088 Table 3 The CR Aeromonas bacteremia group showed tendency disease acquired hospital setting P 0002 7 Outcome analysis nonsurvivors The overall mortality 336 patients 150 50 cases Death occurred median 10 days postadmission Twelve patients died 72 h arrival hospital All nonsurvivors experienced shock Furthermore according univariate analysis cases manifested higher rate resistance antimicrobial agents A number risk factors Aeromonas bacteremiarelated mortality multivariate analysis metastatic cancer shock high Pitt bacteremia score high Charlsons weighted comor bidity index high prothrombin time high serum creatinine level initiation appropriate antimicrobial agents 6 h af ter manifestation symptoms P 005 variables Table 4 The predicted Aeromonas monomicrobial bacteremia mortality rate closely related known Pitt bacteremia score Predicted mortality rate Pitt bacteremia score 0084 0005 100 Discussion Our study included large number cases monomicro bial Aeromonas bacteremia laboratory medical records amenable analysis provide useful information better clinical practice The major clinical categories Aeromonas infection hepatobiliary tract infection peritonitis primary bac teremia These identified 80 ported Aeromonas infections An earlier study common underlying conditions associated Aero monas septicemia malignancy 2150 hepatobili ary diseases 1554 2 4 7 1114 healthy pa tients shown susceptible Aeromonas infection Likewise underlying illness malignancy hepa tobiliary diseases diabetes mellitus frequently en countered Aeromonas bacteremia study As 256 patients present study diabetes mellitus significantly higher rate previously ported 11 5 Our data suggested individuals presenting Aeromonas bacteremia evaluated pos sibility underlying malignancy hepatobiliary diseases diabetes mellitus Previous reports shown patients Aeromonas bacteremia treated broadspectrum βlactam agents thirdgeneration cephalosporins azt reonam imipenem fluoroquinolone 2 5 7 However antimicrobial resistance extendedspectrum cephalosporins cefotaxime clinical Aeromonas isolates noted 1 2 47 11 12 1417 Indeed fluo roquinolone resistance increasing evidenced cip rofloxacinresistance rate 14 previously reported 2 In current study rates resistance ceftriaxone ciprofloxacin imipenem 155 101 98 spectively It shown carbapenemasepro ducing Aeromonas strains MICs imipenem 8 mgL 6 However clinical effect inducible car bapenemases clinical Aeromonas species clearly delineated 2 6 One case study reported imipenemresistant A veronii clinical isolate recovered patient cholangitis case clin ically significant carbapenemresistance Aeromonas spe cies 18 19 A history carbapenem use associated mortality present univariate analysis This suggests previous carbapenem use induce resistance lead poor clinical outcome Based resistance rates data amikacin gentamicin ceftazidime imipenem ciprofloxacin reasonable antimicrobial therapy choices treatment Aeromonas infections Ceftriaxone usual empirical treatment choice patients hepatobiliary infections Ceftriaxone started initial treatment cases suspected gastrointestinal hepatobiliary infection identi fied present study The high resistance patterns led 417 patients treated inappropriate empirical antimicrobial therapy Additionally ceftriaxoneresistant Aer omonas bacteremia groups showed severe clinical manifesta tions laboratory findings The exceptions Aeromonas isolates Jeju University Hospital n 20 susceptible piperacillin piperacillintazobac tam ceftriaxone ceftazidime imipenem ciprofloxacin tobra mycin gentamicin amikacin Thus geographic differenc es affect resistance patterns Recommendations combination therapy Aeromonas bacteremia come studies small number cases polymicro bial monomicrobial bacteremia 20 21 In contrast 03원저_16613_이지영백경란indd 7 20161228 오후 33515 wwwicjournalorg httpsdoiorg103947ic2016484274 Infect Chemother 2016484274284 281 Table 3 Comparison communityacquired vs nosocomial Aeromonas bacteremia ceftriaxoneresistant vs ceftriaxonesusceptible Aeromonas bacteremia Age years Male n Pitt bacteremia score Mortality Site infection n Community acquired n 242 Nosocomial n 94 Pvalue Ceftriaxone susceptible n 284 Ceftriaxone resistant n 52 Pvalue 5848 5200 0013 5912 174 719 62 656 0846 185 136 0333 204 154 5622 32 269 32 132 18 191 0171 38 134 12 231 0578 0338 0008 0088 Hepatobiliary infection 140 579 30 319 0003 136 479 34 654 0003 Spontaneous bacterial peritonitis 54 223 8 85 0003 62 218 0 0 0001 Pneumonia Underlying diseases n Hepatic cirrhosis Solid organ malignancy Devices n 6 25 14 149 0002 12 423 8 154 0006 108 446 24 255 0001 122 430 10 192 105 434 37 394 0056 119 419 23 442 0001 0008 Central line insertion 42 174 38 404 0001 58 204 22 423 0001 Urinary catheter insertion 50 207 32 340 0010 58 204 24 462 0001 Laboratory data mean Hemoglobin gdL Prothrombin time INR Alanine transaminase ALT UL Bilirubin mgdL Glucose mgdL Clinical manifestations n 1058 206 996 796 1668 942 296 1111 1067 2304 0001 1025 0004 0088 0008 188 1336 597 1033 197 2574 674 0001 16098 18269 0506 0021 0001 0093 0207 Shock 64 264 22 234 0566 68 239 18 346 0120 Cardiopulmonary resuscitation 12 50 2 21 0244 6 21 8 154 0001 Mental change 45186 15160 0045 48 169 12 231 Aeromonas isolates 0003 Usage Antimicrobial agent 0445 0004 Initial inappropriate antimicrobial agent 72 298 68 723 0004 44 155 26 500 0001 Initiation antimicrobial agent 6 h 68 281 60 638 0001 34 120 30 577 0001 symptom manifestation Antimicrobial resistance AmpicillinSulbactam Piperacillin 162 669 82 872 0018 202 711 42 807 0351 46 190 42 447 0001 56 197 32 615 0001 PiperacillinTazobactam 28 116 24 255 0001 24 85 28 538 0001 Ceftriaxone Ceftazidime Imipenem Gentamycin Ciprofloxacin 28 116 24 255 0001 6 25 18 191 0001 0 0 2 07 52 100 22 423 0001 21 58 12 128 0009 26 92 10 56 14 149 0001 18 63 7 135 6 115 24 99 10 106 0844 18 63 16 308 0377 0401 0001 03원저_16613_이지영백경란indd 8 20161228 오후 33515 282 Rhee JY et al Clinical implications Aeromonas bacteremia wwwicjournalorg Table 4 Risk factors fatality Aeromonas bacteremia Table 4 Continued Odd ratio 95 confi dence interval Pvalue Univariate analysis Underlying disease Chronic renal failure 14737 0001 Metastatic cancer Diabetes mellitus Cerebrovascular attack Quadriparesis Myocardial infarct Pitt bacteremia score Charlson weighted comorbidity index Primary site infections Hepatobiliary origin Skin softtissue infection Clinical manifestations Shock Altered mental status Hypothermia Cardiopulmonary resuscitation Acute renal failure Devices Central line Urinary catheterization Ventilator Laboratory data Hemoglobin gdL Prothrombin time INR activated partial thromboplastin time aPTT Albumin gdL Bilirubin mgdL Aspartate transaminase AST UL Alanine transaminase ALT UL Blood urea nitrogen mgdL Creatinine mgdL Glucose mgdL Potassium mmolL Antimicrobial resistance Resistance Tobramycin Resistance Gentamicin 7154 5603 4367 4367 4367 50871 5473 8064 4739 35861 56179 24029 25005 23520 17546 29127 4850 3177 16159 4395 2699 11266 3382 3641 3329 0007 0018 0037 0037 0037 0001 0019 0005 0034 0001 0001 0001 0001 0001 0001 0001 0028 0003 0000 0036 0011 0001 0001 0001 0011 30617 0001 6024 6121 4840 3969 0014 0013 0028 0046 Odd ratio 95 confi dence interval Pvalue 4367 4786 0037 0029 0445 0049 13064 0001 Resistance Amikacin History Previous carbapenem use Initiation antimicrobial agent 6 h symptom manifestation Initial inappropriate antimicrobial agent Duration antimicrobial agents 18292 0001 Others Previous hepatobiliary operation Aeromonas hydrophila 7147 8064 Multivariate analysis Metastatic cancer Shock Pitt bacteremia score Charlson weighted comorbidity index Prothrombin time INR Creatinine mgdL Initiation antimicrobial agent 6 h manifesting symp toms 7166 53549004 3909 32145417 6486 198021249 1536 10222309 2446 12704709 4093 116514376 0527 01120912 0028 0005 0003 0048 0002 0039 0007 0028 0043 current study significant difference clinical outcomes patients definitively treated monotherapy combination therapy However recommend monotherapy combination therapy treatment Aeromonas bacteremia point proportion inappropriate initial therapy high ex perience Given lack available therapeutic options Aeromonas bacteremia wellcontrolled clinical trials com binations existing antibiotics urgently needed A caviae frequent pathogen causing Aeromonas bacteremia Japan 19 22 A hydrophila followed A veronii biovar sobria common Aeromonas species causing bacteremia Taiwan 23 In study A hydrophila common Aeromonas species caus 03원저_16613_이지영백경란indd 9 20161228 오후 33516 wwwicjournalorg httpsdoiorg103947ic2016484274 Infect Chemother 2016484274284 283 ing bacteremia followed A caviae interesting Korea geographically located China Japan Therefore additional epidemiological studies required order establish bacteriology different types Aero monas infections different regions Isolates need col lected links genetic factors geographic areas analyzed This relevant study A hydrophila showed higher antimicrobial resistance sulted greater clinical severity Aero monas spp P 005 The mortality rates patients Aeromonas bacte remia range 28 63 literature 1 2 4 7 18 24 25 However study showed significantly lower mortality rate 149 In cases patients skin softtissue fection worse clinical outcomes secondary bacteremia finding statistically significant univariate analysis Bacterial peritonitis asso ciated approximate 15 mortality rate necrotiz ing fasciitis higher mortality rate 50 death patients In study number patients necro tizing fasciitis 14 We postulated lower mortality rate study associated low prevalence softtissue infection relatively low rate liver cir rhosis 7 Inappropriate therapy regarded prog nostic factor patient outcomes 26 correlated mortality study The main limitation study retrospective sign As specific information antibiotic types cefepime aztreonam missing medical records Furthermore study conducted tertia ry hospitals examined data spanning 14 years During time medical microbiological environments changed results generalized hospitals In conclusion patients Aeromonas bacteraemia treated carbapenem ceftazidime fluoroquinolone Al Aeromonas species showed higher resistance rate ceftriaxone Aeromonas bacteremia correlated rel atively low mortality rate compared previous studies All nonsurvivors experienced shock Ceftriaxonebased metronidazole combination treatment recom mendable initial empirical therapy particular high antimicrobial resistance rates agents septicshock patients In patients septic shock carbapen embased aminoglycoside combination treatment considered initial empirical therapy high antimicrobialresistance rates agents present septic shock Considering risk factors mortality ade quate antibiotics given early especially patients shock impaired renal function In order rec ommendations definitive therapy based available sus ceptibility results studies larger numbers cases supportive experiment DNA sequencing warranted Conflicts Interest No conflicts ORCID JiYoung Rhee httporcidorg0000000346647048 Kyong Ran Peck httporcidorg0000000274649780 References 1 Tsai MS Kuo CY Wang MC Wu HC Chien CC Liu JW Clinical features risk factors mortality Aero monas bacteremic adults hematologic malignancies J Microbiol Immunol Infect 2006391504 2 Wu CJ Wu JJ Yan JJ Lee HC Lee NY Chang CM Shih HI Wu HM Wang LR Ko WC Clinical significance distri bution putative virulence markers 116 consecutive clinical Aeromonas isolates southern Taiwan J Infect 2007541518 3 Lee WS Puthucheary SD Retrospective study Aero monas infection Malaysian urban area 10year ex perience Singapore Med J 2001425760 4 Mandell GL Bennett JE Dolin R eds Mandell Douglas Bettetts Principles practice infectious diseases 6th ed Philadelphia Elsevier Churchill Livingstone 2005 5 Llopis F Grau I Tubau F Cisnal M Pallares R Epidemio logical clinical characteristics bacteraemia caused Aeromonas spp compared Escherichia coli Pseudomonas aeruginosa Scand J Infect Dis 20043633541 6 Ko WC Wu HM Chang TC Yan JJ Wu JJ Inducible talactam resistance Aeromonas hydrophila therapeu tic challenge antimicrobial therapy J Clin Microbiol 199836318892 7 Ko WC Lee HC Chuang YC Liu CC Wu JJ Clinical features therapeutic implications 104 episodes monomi crobial Aeromonas bacteraemia J Infect 20004026773 03원저_16613_이지영백경란indd 10 20161228 오후 33516 284 Rhee JY et al Clinical implications Aeromonas bacteremia wwwicjournalorg 8 Choi JP Lee SO Kwon HH Kwak YG Choi SH Lim SK Kim MN Jeong JY Choi SH Woo JH Kim YS Clinical sig nificance spontaneous Aeromonas bacterial peritonitis cirrhotic patients matched casecontrol study Clin Infect Dis 2008476672 9 Rhee JY Kwon KT Ki HK Shin SY Jung DS Chung DR Ha BC Peck KR Song JH Scoring systems prediction mortality patients intensive care unitacquired sepsis comparison Pitt bacteremia score acute physiology chronic health evaluation II scoring systems Shock 2009 3114650 10 Clinical Laboratory StandardsInstitute CLSI Perfor mance Standards Antimicrobial Susceptibility Testing Fifteenth informational supplement Wayne PA CLSI 2005M100S11 11 Campo C Navarro V Pérez C Gutiérrez I Alonso R Aero monas spp bacteremia study 12 cases review literature Enferm Infecc Microbiol Clin 2001191614 12 Ko WC Chuang YC Aeromonas bacteremia review 59 episodes Clin Infect Dis 1995201298304 13 Lai CC Shiao CC Lu GD Ding LW Aeromonas hydrophi la Aeromonas sobria bacteremia rare pathogens infection burn patient Burns 2007332557 20061147728 17 Sebo P Sakbani K Rohner P Gavazzi G Aeromonas bac teremia elderly immunocompetent patient Aging Clin Exp Res 2006183446 18 SánchezCéspedes J Figueras MJ Aspiroz C Aldea MJ Toledo M Alperí A Marco F Vila J Development imipe nem resistance Aeromonas veronii biovar sobria clinical isolate recovered patient cholangitis J Med Microbiol 2009584515 19 GarcíaIrure JJ Navascués A Vivanco M Rodrígo A Spon taneous bacterial peritonitis bacteraemia Aer omonas hydrophila An Sist Sanit Navar 20032642931 20 Funada H Matsuda T Aeromonas bacteremia patients hematologic diseases Intern Med 1997361714 21 Harris RL Fainstein V Elting L Hopfer RL Bodey GP Bac teremia caused Aeromonas species hospitalized cancer patients Rev Infect Dis 1985731421 22 Kimura M Araoka H Yoneyama A Aeromoans caviae frequent pathogen cases Aeromonas bacteremia Japan Scand J Infect Dis 2013453049 23 Kao HT Huang YC Lin TY Fatal bacteremic pneumonia caused Aeromonas hydrophila previously healthy child J Microbiol Immunol Infect 20033620911 14 Lau SM Peng MY Chang FY Outcomes Aeromonas bacteremia patients different types underlying disease J Microbiol Immunol Infect 2000332417 24 Tang HJ Lai CC Lin HL Chao CM Clinical manifestations bacteremia caused Aeromonas species southern Taiwan PLoS One 20149e91642 15 Doudier B Imbert G Vitton V Kahn M La Scola B Aero monas septicaemia uncommon complication follow ing placement transhepatic biliary drainage devices Europe J Hosp Infect 2006621156 25 Tena D GonzálezPraetorius A Gimeno C PérezPomata MT Bisquert J Extraintestinal infection Aeromonas spp review 38 cases Enferm Infecc Microbiol Clin 20072523541 16 Huang LJ Chen HP Chen TL Siu LK Fung CP Lee FY Liu CY Secondary Aeromonas peritonitis associated polymicrobial ascites culture absence liver cirrho sis compared primary Aeromonas peritonitis APMIS 26 Kim J Lee Y Park Y Kim M Choi JY Yong D Jeong SH Lee K Anaerobic bacteremia impact inappropriate therapy mortality Infect Chemother 201648918 03원저_16613_이지영백경란indd 11 20161228 오후 33516